AorticLab

AorticLab is a high-tech startup that focuses on providing advanced solutions for the treatment of severe AORTIC STENOSIS. The company's mission is to address the needs of patients suffering from this condition, offering hope to those who previously had limited treatment options due to age or health constraints. AorticLab aims to advance the standards of aortic stenosis treatment by enabling safer TAVI procedures, minimizing the risks of cerebral and peripheral complications. The company's dedication to improving patients' quality of life is evident in its innovative product development. AorticLab is currently developing FLOwer, an Embolic Protection Device, and GEMINI, a Transcatheter Treatment, both of which offer promising solutions for the effective and less invasive treatment of aortic stenosis. With a foundation built on extensive experience and a passionate, pioneering approach, AorticLab is poised to make a significant impact in the field of cardiovascular health. As of September 20, 2021, AorticLab secured a €1.50M Debt Financing investment from UniCredit, bolstering its endeavors to bring its products to market. The company's headquarters are situated in Italy, and it is set to release FLOwer commercially in 2023 in selected European countries. AorticLab's commitment to innovation and patient safety positions it as a promising venture for potential investors seeking to contribute to the advancement of cardiovascular care and medical technology.